BMS 599626

Drug Profile

BMS 599626

Alternative Names: AC480; BMS599626

Latest Information Update: 23 Jul 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Ambit Biosciences Corporation
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Glioma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 23 Jul 2015 Discontinued - Phase-I for Breast cancer, Glioma, Non-small cell lung cancer and Solid tumours (Combination therapy) in USA after October 2013 (IV)
  • 22 Jun 2015 Ambit Biosciences withdraws phase-I trial in Solid tumours in USA prior to enrolment (Combination therapy) (NCT01245543)
  • 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top